Financials data is unavailable for this security.
View more
Year on year Concord Biotech Ltd grew revenues 18.01% from 10.17bn to 12.00bn while net income improved 20.62% from 3.08bn to 3.72bn.
| Gross margin | 57.97% |
|---|---|
| Net profit margin | 26.85% |
| Operating margin | 31.63% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2025, cash reserves at Concord Biotech Ltd fell by 142.38m. However, the company earned 2.45bn from its operations for a Cash Flow Margin of 20.37%. In addition the company used 1.60bn on investing activities and also paid 987.68m in financing cash flows.
| Cash flow per share | 36.23 |
|---|---|
| Price/Cash flow per share | 30.70 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 22.29% and 20.62%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 35.88% |
| EPS growth(5 years) | 17.06 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -19.46 |
More ▼
